Partisan battles and nearly constant conflict across multiple government policy fronts – from immigration and border security to the trade war with China – continued to dominate the headlines in Washington throughout much of 2018, nearly overshadowing national gains from resurgent economic growth and culminating in mid-term congressional elections that altered the balance of power in D.C. Despite these challenges, AdvaMed was able to cut through the din in Washington and elsewhere – working with allies and champions on every side of the political divide – to achieve important, bipartisan health policy wins for our members and the patients they serve.
Throughout the year, AdvaMed was there when it matters for our member companies, just as they are there when it matters for the millions of patients who depend on medical technology every day. From advancing medical device tax relief to strengthening the industry’s well-earned reputation for providing innovative, safe and effective solutions to the world’s health care challenges, our work together achieved critical results on behalf of industry and patients everywhere. In brief, AdvaMed’s advocacy successes in 2018 included:
- Renewed suspension of the medical device tax and ongoing advocacy for permanent repeal, enactment of legislation to expand use and awareness of medtech as an alternative to opioids, and broadened state-level advocacy that is paying key dividends in California and across the nation;
- Ensuring effective implementation of key provisions we supported as part of the FDA Reauthorization Act, the latest medical device user fee agreement, and 21st Century Cures, to help speed patient access to innovation;
- Advancement of key Medicare coverage and payment reform proposals to help make the process more predictable and to speed access to innovation, and achievement of increased transparency and accountability in the Medicare local coverage decision process;
- Achievement of key international objectives, such as significant improvements in regulatory time to market in China and Brazil, prevention of centralized pricing in China, preservation of reimbursement levels in Japan, as well as ongoing work to address price controls in India, challenges with adoption of new device regulations in Europe, and tariffs on medtech in the trade war with China;
- Continued advancement of legislative and administrative proposals for new safe harbors to the U.S. anti-kickback statute (to enable more expansive and patient-centric value-based payment arrangements), increased global harmonization of high-standard codes of ethics, and completion of a comprehensive refresh of AdvaMed’s Code of Ethics;
- Progress in AdvaMedDx advocacy for diagnostics regulatory reforms to spur innovation, legislative and administrative efforts to improve implementation of lab test payment reforms, and promotion of the value of diagnostics in public health initiatives;
- Continued advocacy through AdvaMed Accel for legislation that promotes investment in small firms, and advancement of initiatives that bring together more stakeholders in the innovation ecosystem; and
- Presentation of our largest and most successful MedTech Conference ever in Philadelphia.
For more details on these and other highlights of 2018, and related photo galleries, please click on the topic areas listed on the right of this webpage....
Chief Executive Officer
Chief Executive Officer